IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

IO Biotech, a clinical-stage biopharmaceutical company focused on developing immune-modulating cancer vaccines, has achieved a significant milestone in its global Phase 3 clinical trial for IO102-IO103. The company has randomized 225 patients with advanced melanoma in combination with pembrolizumab. The trial protocol calls for an interim analysis of overall response rate one year after the enro..